Induction and large-scale expansion of CD8+ tumor specific cytotoxic T lymphocytes from peripheral blood lymphocytes by in vitro stimulation with CD80-transfected autologous melanoma cells

European Cytokine Network

Volumn 10, Issue 3, 1999, Pages 329-335

  Mackensen, Andreas ^a   Wittnebel, Sebastian ^a   Veelken, Hendrik ^a   Noppen, Christoph ^b   Spagnoli, Giulio C ^b   Lindemann, Albrecht ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Adoptive immunotherapy; B7; CTL; Melanoma

Indexed keywords

B7 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MELANOMA CELL; PERIPHERAL LYMPHOCYTE; PHENOTYPE; T LYMPHOCYTE ACTIVATION;

ADOPTIVE TRANSFER; ANTIGENS, CD80; BASE SEQUENCE; CELL DIVISION; CYTOTOXICITY, IMMUNOLOGIC; DNA PRIMERS; HUMANS; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MELANOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 0032864995     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. van den Eynde B J, van der Bruggen P. 1997. T cell defined tumor antigens. (Review) Curr. Opin. Immunol. 9: 684.
2. Mackensen A, Carcelain G, Viel S, Raynal MC, Michalaki H, Triebel F, Bosq J, Hercend T. 1994. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J. Clin. Invest. 93: 1397.
3. Chen L, Linsley PS, Hellström KE. 1993. Costimulation of T cells for tumor immunity. (Review) Immunol. Today 14: 483.
4. Gimmi C D, Freeman G J, Gribben J G, Gray G, Nadler L M. 1995. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA 90: 6586.
5. Lenschow D J, Walunas T L, Bluestone J A. 1996. CD28/B7 system of T cell costimulation. (Review) Annu. Rev. Immunol. 14: 233.
6. Döhring C, Angman L, Spagnoli G, Lanzavecchia A. 1994. T-helper-and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int. J. Cancer 57: 754.
7. + cytotoxic T lymphocytes in vitro. Hum. Gene Ther. 9: 1335.
8. Yang S, Darrow T L, Seigler H F. 1997. Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogenic peripheral blood lymphocytes by B7 gene-modified melanoma cells. Cancer Res 57: 1561.
9. Veelken H, Re D, Kulmburg P, Rosenthal F M, Mackensen A, Mertelsmann R, Lindemann A, 1996. Systemic evaluation of chimeric marker genes on dicistronic transcription units for regulated expression of transgenes in vitro and in vivo. Hum. Gene. Ther. 7: 1827.
10. Noppen C, Spagnoli G C, Schaefer C. 1996. Isolation of multiple mRNAs from a few eukaryotic cells: a fast method to obtain templates for RT-PCR. Biotechniques 21: 394.
11. Mackensen A, Veelken H, Lahn M, Wittnebel S, Becker D, Köhler G, Kulmburg P, Brennscheidt U, Rosenthal F, Franke B, Mertelsmann R, Lindemann A. 1997. Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts. J. Mol. Med. 75: 290.
12. Hercend T, Meuer S, Brennan A, Edson M A, Acuto O, Reinherz E L, Schlossman S F, Ritz J. 1983. Identification of a clonally restricted 90 kD heterodimer on two human cloned natural killer cell lines. J. Exp. Med. 158: 1547.
13. Sule-Suso J, Arienti F, Melani C, Colombo M P, Parmiani G. 1995. A B7-l-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogencic lymphocytes. Eur. J. Immunol. 25: 2737.
14. Harada M, Okamoto T, Omoto K, Tamada K, Takenoyama M, Hirashima C, Ito O, Kimura G, Nomoto K. 1996. Specific immunotherapy with tumor-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies. Immunology 87: 447.
15. Gajewski T F, Renauld J C, Van Pel A, Boon T. 1995. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J. Immunol. 154: 5637.
16. Lynch D H, Miller R E. 1994. Interleukin-7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J. Exp. Med. 179: 31.
17. Coughlin C M, Wysocka M, Kurzawa H L, Lee W M, Trinchieri G, Eck S L. 1995. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res. 55: 4980.
18. Gajewski T F, Fallarino F, Uyttenhove C, Boon T. 1996. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156: 2909.
19. Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler L M, Griffin J D. 1996. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T-cell mediated anti-leukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156: 1126.
20. + T lymphocytes by B7, a natural ligand for CD28, can be utilized to treat established mouse melanoma. J. Immunol. 153:421.
21. Walter E A, Greenberg P D, Gilbert M J, Finch R J, Waranabe K S, Thomas E D, Riddell S R. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T cell clones from the donor. N. Engl. J. Med. 333: 1038.
22. Papadopoulos E B, Ladanyi M, Emanuel D, Mackinnon S, Boulard F, Carabasi M H, Castro-Malaspina H, Childs B H, Gillio A P, Small T N, Young J W, Kernan N A, O'Reilly R J. 1994. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330: 1185.
23. Mogi S, Ebata T, Setoguchi Y, Fujime M, Heike Y, Kohsaka T, Yagita H, Okumura K, Azuma M. 1998. Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2. Clin. Cancer Res. 4: 713.